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Patterns of Radiotherapy Re-Treatment in Patients with
Lung Cancer: A Retrospective, Longitudinal Study
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and Shalini K. Vinod, MBBS (Hons), MD, FRANZCR,*†
Introduction: The optimal initial radiotherapy utilization rate for
lung cancer is estimated to be 76% of all new cases. The actual
re-treatment rate has not been defined. Re-treatment information can
aid clinical decision making and resource planning. The aim of this
study was to examine the indications for re-treatment in a population
cohort and report the proportion of patients who receive more than
one radiotherapy treatment for lung cancer throughout their lifetime.
Methods: A retrospective longitudinal analysis of a cohort of
patients with lung cancer treated with radiotherapy in the South
Western Sydney Area Health Services (SWSAHS) in 1993 and 1996
was performed. The indication for and timing of all episodes of
radiotherapy were recorded and analyzed using SPSS Data 3.5
software (SPSS, Inc., Chicago, IL).
Results: Of the 527 patients diagnosed with lung cancer in the study
period, 279(53%) were treated at least once with radiotherapy.
Initial radiotherapy was palliative for 79%, definitive for 14%, and
adjuvant for 7%. The most common sites of initial radiotherapy were
chest (79%), bone (10%), and brain (9%). Of the 279 patients, 73
(27%) received treatment with a second course of radiotherapy, 19
(7%) had a third radiotherapy episode, and 6 (2%) had a fourth. One
patient had five radiotherapy episodes. Overall, there were 328
radiotherapy courses delivered to the 279 patients.
Discussion: The re-treatment rate for our cohort was 27%, exceed-
ing other estimations of re-treatment. Common sites re-treated were
chest and bone. Re-treatment was 17% of the initial linear acceler-
ator treatment delivery work load for lung cancer.
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Investigators have defined the optimal proportion of newcases of cancer that should receive radiotherapy (radiother-
apy utilization rate) by examining the indications for radio-
therapy at various cancer sites.1 Radiotherapy utilization rates
can aid clinicians in identifying a benchmark for optimal
treatment and planning future radiotherapy resources. In the
past, these rates have not included re-treatment among pa-
tients who develop recurrent local or distant disease.2
Delaney et al.1 estimated the demand for re-treatment by
applying an overall factor of 1.25 when converting from the
number of patients with an indication for radiotherapy to the
actual number of treatment courses per incident case based on
observed clinical practice. In a report on radiotherapy in
Australia 2002, it was estimated that 20% of all radiotherapy
courses in New South Wales were re-treatments based on
linear accelerator work patterns but did not provide informa-
tion regarding re-treatment rates for individual tumor sites.3
Data on re-treatment are sparse; therefore, the actual and
optimal re-treatment rates for various cancer sites remain
unknown.
Lung cancer is the fourth most common malignancy in
Australia and the most common cause of cancer-related
mortality.4 It is a significant cause of morbidity, requiring a
multidisciplinary approach to management. Radiotherapy is a
treatment modality with indications in all stages of lung
cancer. The initial radiotherapy utilization rate has been
estimated to be 76%,1 accounting for the first radiotherapy
episode delivered. Most patients present with advanced dis-
ease, and there is a high rate of loco-regional and distant
recurrence. There have been series in the literature indicating
that re-treatment of local chest disease is effective, with
improvement in symptoms in 50% to 80%,5–7 and the pallia-
tive benefit of treating symptomatic distant metastases is well
established. Therefore, it is reasonable to assume that a
proportion of patients with lung cancer would require radio-
therapy re-treatment at some time. Although an overall aver-
age re-treatment rate of 20% may seem reasonable, it may
underestimate the actual re-treatment rate for lung cancer,
and it gives no information about the patterns of treatment to
various sites.
The primary aim of this study was to identify the
indications for and the prevalence of patients with lung
cancer who undergo radiotherapy re-treatment. We also as-
sessed the impact of re-treatment on radiotherapy workload.
MATERIALS AND METHODS
The study cohort was taken from a preexisting data set
of patients in the South Western Sydney Area Health Service
(SWSAHS) diagnosed with lung cancer in the years 1993 and
1996 as documented by the New South Wales Central Cancer
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Registry.8 This is a population-based registry that receives
statutory notification of all cancer diagnoses in New South
Wales. Accuracy of case identification was improved by
searching the databases of the cancer care centers where the
patients were treated. The incident cases were SWSAHS
residents (defined by postal code) diagnosed with lung cancer
in the years 1993 and 1996. Medical and oncology records
were reviewed retrospectively to collect patient data, includ-
ing demographics, tumor characteristics, investigations, treat-
ment details, and outcomes. Events were documented from
the time of initial radiotherapy and included the initial radio-
therapy indication, the development of metastatic disease or
recurrence requiring radiotherapy, and the actual radiother-
apy given. The number of radiotherapy courses, interval
between courses, number of fractions, and number of fields
were noted. Details regarding response to therapy and patient
performance status were not available because of lack of
availability of such information.
RESULTS
Demographics
In 1993 and 1996, 527 patients were diagnosed with
lung cancer in the SWSAHS. Of these patients, 279 received
radiotherapy as part of their treatment and were analyzed in
this study. Seventy-one percent were men, and 29% were
women. The median age at diagnosis was 68 years. There was
no difference in demographics between the radiotherapy
treatment group and the overall lung cancer population. Of
the patients, 74% had non-small cell lung cancer (NSCLC),
and the stage at presentation (UICC 1992) was I for 10%, II
for 5%, III for 50%, and IV for 35%. Another 14% of patients
(39 of 274) had small cell lung cancer (SCLC); 26 had
limited-stage SCLC and 13 had extensive-stage SCLC. The
remaining 12% had other histology or the diagnosis was
unknown. Histopathological subtypes were as follows: 14%
SCLC, 32% squamous cell carcinoma, 22% adenocarcinoma,
23% large cell carcinoma, 0.4% mixed type, 4% mesotheli-
oma, and 3.2% no recorded histopathology.
Radiotherapy
Of the patients, 52% percent of patients (279 of 527)
received at least one course of radiotherapy. Radiotherapy
treatment details were not available for four patients. Of those
receiving radiotherapy, 64% were treated with one radiother-
apy course, and 36% received more than one radiotherapy
course. Twenty-seven percent were treated twice, 7% re-
ceived three treatment courses, and 2% had four treatment
courses. One patient received five radiotherapy courses.
There were a total of 373 radiotherapy courses given to
275 patients, an average of 1.36 courses per patient. The first
treatment episode was definitive in 14%, adjuvant in 7%, and
palliative in 79% of patients. All subsequent courses deliv-
ered were for palliation.
The pattern of treatment delivered is shown in Figure 1.
Most initial chest radiotherapy was delivered for palliation;
however 62 of 219 patients had treatment with definitive or
adjuvant intent. Subsequent treatments were primarily for
distant relapse; however, a small proportion of patients (12 of
219) required re-treatment to the chest, with one patient being
treated four times to the primary lung site. After initial chest
radiotherapy with curative intent, nine patients had brain
radiotherapy. Four of these nine patients were treated with
prophylactic cranial irradiation, and five patients were treated
for relapsed disease. Of the patients who received initial
treatment for bone metastases, they were most likely to have
subsequent treatment for bone metastases. Of the patients
treated for brain metastases first, only a small number (7 of
25) had further treatment for bone or chest disease.
Figure 2 shows the pattern of re-treatment in our cohort
by treatment site and radiotherapy course compared with the
optimal initial radiotherapy utilization data from Delaney et
al.1 Each bar represents the number of patients that could
have received a course of radiotherapy at that stage and
shows the proportion of the cohort receiving subsequent
courses of radiotherapy and the site treated.
Compared with the optimal radiotherapy data, our co-
hort had a lower initial radiotherapy utilization rate, with
initial treatment to the chest less than the optimal rate, and
treatment to distant metastatic disease (such as bone metas-
tases) treated at a higher rate.
After the first treatment course, the pattern of re-
treatment was similar for subsequent courses. The proportion
of patients who had an initial radiotherapy treatment course in
our cohort was 52%, and the proportion of those who had
subsequent treatment episode was approximately 25% to 30%
for each successive episode.
Initial radiotherapy was delivered to local disease in the
chest in most cases (79%) with bone disease treated in 10%,
brain disease in 9%, and other sites of disease in 2%.
The second treatment episode with radiotherapy was
typically to treat bone metastases (40%) or brain metastases
(33%), but local disease was also treated in 22%. Other sites
of relapsed disease, such as lymph nodes, accounted for 5%.
A third treatment episode was delivered to 19 patients
(7%) and was largely given for bone metastases (63%), local
relapse (21%), brain metastases (11%), and other sites (5%).
Six patients received a fourth episode of radiotherapy,
four for bone metastases and two for local metastases.
Only one patient had a fifth radiotherapy episode for
bone metastases.
Non-Small Cell Lung Cancer and Stage
There were 207 patients with NSCLC treated with
radiotherapy. Disease was stage I in 20 patients, stage II in 10
patients, stage III in 104 patients, and Stage IV in 72 patients.
These 207 patients received 281 radiotherapy treatment epi-
sodes, so that each patient received an average of 1.36
treatments.
Most treatments for NSCLC were initially palliative in
intent. Curative or adjuvant radiotherapy ranged from 46% in
stage IIIA to19% in stage IIIB. Figure 3 demonstrates the
proportion of radiotherapy treatments delivered to patients
based on disease stage at presentation and site treated. For
example, among the patients treated with radiotherapy who
had stage I disease at diagnosis, 62% of courses were for local
disease, 17% were for bone relapse, and 21% were for brain
relapse. The primary site was more likely to be treated in
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patients with stage IIIA and IIIB disease, who would be more
likely to have symptomatic primary tumors and less indica-
tion for surgery. Patients with stage IIIA disease were more
likely to require more than one radiotherapy treatment, with
36% undergoing more than one treatment episode. In com-
parison, the proportion of patients receiving more than one
radiotherapy treatment course was 10% for stage I, 20% for
stage II, 25% for stage IIIB, and 26% for stage IV disease.
This reflects the natural history and treatment of stage IIIA
FIGURE 2. Radiotherapy treatment sites by number of
treatment courses. Optimal data derived from Delaney et al.1
FIGURE 3. Proportion of radiotherapy treatments by treat-
ment site and tumor stage for patients with non-small cell
lung cancer (n  207).
FIGURE 1. Pattern of radiotherapy
therapy treatment for patients with
lung cancer (n  275).
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disease, which would include a group who would receive
definitive or adjuvant radiotherapy initially, and then further
radiotherapy for distant or local relapse (Figure 4).
Small Cell Lung Cancer
Of the 39 patients diagnosed with SCLC, 26 had
limited-stage disease and 13 had extensive-stage disease.
There were 57 radiotherapy episodes delivered to this group,
an average of 1.46 per patient. Figure 5 demonstrates the
proportion of radiotherapy courses delivered to various sites
for limited- and extensive-stage disease. The sites treated
seem to be different between the two groups. Chest radio-
therapy was more likely to be delivered to the limited-stage
group as part of potentially curative treatment, whereas dis-
tant disease was more likely to be treated in the extensive-
stage group. Only 12 of 26 patients with limited-stage disease
were treated with definitive or adjuvant intent, and 4 received
prophylactic cranial irradiation after their treatment for local
disease. This could have been related to patient factors
indicating a poor prognosis, such as weight loss or poor
performance status. Forty-two percent of patients with limit-
ed-stage disease and 31% with extensive-stage disease re-
ceived more than one radiotherapy treatment, which may
reflect burden of disease and patient performance status in
this group.
Dose and Fractionation
The total dose of radiotherapy delivered decreased with
each successive episode. The median dose was 30 Gy for the
first episode, 20 Gy for the second, 15 Gy for the third, 14 Gy
for the fourth, and 8Gy for the patient receiving a fifth
treatment.
The median dose per fraction also increased with each
subsequent episode as follows: 3 Gy per fraction for the first
episode, 4 Gy per fraction for the second and third episodes,
6 Gy per fraction for the fourth episode, and 8 Gy per fraction
for the fifth episode.
Correspondingly, the total number of fractions deliv-
ered per treatment episode decreased from a median of 10 for
the first radiotherapy episode, to 5 for the second and third
episodes, to 3 for the fourth episode, and 1 for the fifth
episode.
The total number of fractions delivered for the initial
treatment to our patients was 3284, which corresponds to a
mean 12 fractions per treatment course. The total number of
fractions in the re-treatment setting was 583, a mean of 4
fractions per course. Therefore, although the total number of
re-treatment episodes was 36% of the total number of initial
treatment episodes, the total number of fractions for re-
treatment was only 17% of the total number of fractions
delivered at the first radiotherapy treatment episode.
Time Between Treatment Courses
The mean duration of time between the first and second
courses of radiotherapy was 108 days, and it was 80 days for
time between the second and third courses. The mean time
between episodes was 30 days.
DISCUSSION
In this cohort of patients with lung cancer, 52% re-
ceived one course of radiotherapy, and approximately 33%
received more than one course of radiotherapy during their
illness, which is higher than the crude estimation of re-
treatment rate provided by NSW Health.3 The rate of subse-
quent re-treatments is approximately 30%, and the overall
proportion of re-treatments to initial treatment is approxi-
mately 36%.
The initial radiotherapy utilization rate was lower than
that considered optimal based on treatment guidelines and
best current evidence. The distribution of treatment sites at
first treatment indicated a possible under-treatment of chest
disease that could be the result of clinicians only referring
patients after the development of distant metastases, thus
limiting the potential benefit to patients in terms of survival
and quality of life. Once identified, these patterns could give
clinicians insight into referral and treatment patterns and aid
the development of interventions to improve and optimize
patient care.
Most initial radiotherapy was delivered to the primary
site, and most re-treatments were delivered to distant metas-
tases, mirroring the pattern of relapse for most patients,
although a small number of patients required re-treatment of
the primary lesion. As the number of treatment episodes
increase, the mean duration between each episode decreases.
The total dose and number of fractions also decrease, reflect-
ing the poorer performance status and prognosis of patients
toward the end stage of their disease. This can have implica-
tions for linear accelerator workload planning.
When we analyzed the cohort by histology and stage,
we found that, for NSCLC, the likelihood of re-treatment was
highest for patients with stage III disease, which is consistent
FIGURE 4. Proportion of patients with non-small cell lung
cancer who underwent more than one radiotherapy treat-
ment (n  207).
FIGURE 5. Proportion of radiotherapy treatments by treat-
ment site and tumor stage among patients with small cell
lung cancer (n  57).
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with the pattern of presentation, initial treatment, and relapse
among this group of patients. The rate of re-treatment of
recurrent disease is less than the expected incidence of
recurrence, which is approximately 20% to 40% in early-
stage disease and up to 80% in stage III disease,9–11 again
suggesting that radiotherapy may have been under-utilized in
a re-treatment setting in our cohort. Among patients with
SCLC, those with limited-stage disease were more likely to
receive re-treatment. These results imply that re-irradiation
may be under-utilized, although it may also be a reflection of
patient performance status, patient acceptance of further
treatment, or clinician bias.
In their patterns of care study, Vinod et al.5 demon-
strated that management of the 527 patient cohort was po-
tentially suboptimal. Of the patients, 9% did not have a
pathological diagnosis, and 12% were not referred to a lung
cancer specialist at all (specialist referral decreased with
increased patient age). Among the patients, 28% received no
anti-neoplastic treatment for any indication, including palli-
ation. In addition, 31% of the patients not treated were never
seen by a specialist, indicating that the decision for no
treatment was made by the individual and/or general practi-
tioner without specialist oncology input. The radiotherapy
utilization rate was low (52%), as was that for chemotherapy
(21%). The reasons for this potential under-treatment are
likely to be multifactorial and could include patient factors
such as poor performance status, co-morbidity, or advanced
age (21% were older than 70 years); treatment factors such as
accessibility to specialist care; or patient/practitioner nihil-
ism. Other treatment factors include indications for treatment
at the time; for example, the role of adjuvant chemotherapy
was not well defined until recently.12 After Vinod et al.’s
patterns of care study, attempts have been made to improve
patient care in the region. Access to both radiotherapy and
chemotherapy has improved with increased staff and facili-
ties, multidisciplinary meetings are held regularly, and inter-
departmental communication and cooperation is encouraged.
The appointment of a tumor site care coordinator aims to
improve patient access and utilization of current services.
Information workshops have been organized to educate the
public and primary health practitioners to improve primary
referral rates to the oncology service, and patient data are
being collected prospectively to access impact on patterns of
care in the future. Positron emission tomography scanning is
readily available and can improve patient selection for ag-
gressive treatment. Chemotherapy has been identified as
having a role in the adjuvant setting, and its increased
delivery could change the pattern of relapse to further affect
radiotherapy treatment patterns. Future patterns of care stud-
ies would be helpful in establishing the current pattern of
radiotherapy utilization and how it may have been affected by
these factors.
A major limitation of our study is that it is a snapshot
of a retrospective cohort of patients from 1993 and 1996. It is
possible that changes in the management of patients with lung
cancer in the region will mean that this cohort is not repre-
sentative of patients treated in SWSAHS in 2007, especially
with regard to initial radiotherapy utilization. However, we
were able to use a well-constructed and detailed preexisting
database from which to derive and relate our re-treatment
findings. This gives reasonable initial re-treatment estimation
for patients with lung cancer, which can be further investi-
gated. It is not clear whether the initial low radiotherapy
utilization rate in our cohort would affect re-treatment. We
postulate that this may not actually affect re-treatment dra-
matically, as once patients have at least one treatment with
radiotherapy; they become known to the radiotherapy depart-
ment. As a result, they would be more likely to be followed
by the radiation oncologist and considered for re-treatment if
appropriate, with the limiting parameters more likely to be
related to patient wishes, performance status, and medical
condition. A further significant limitation is that the quality of
data collected was dependent on documentation from hospital
paper records, which were generally poor and difficult to
access. Because of limited data on performance status, actual
relapse incidence, and details regarding patient referral and
decision making, we were unable to estimate an optimal
re-treatment rate for patients with lung cancer. In some
instances, it was also difficult to clarify unusual treatment
patterns, such as multiple radiotherapy delivery to the pri-
mary site. Most departments are now keeping electronic
databases, which should make future patterns of care assess-
ment easier. A potential future study would review patterns of
care in the area, including re-treatment, comparing current
practice with that in 1993 and 1996.
Future studies in this area would be useful for a number
of reasons. A prospective analysis would allow collection of
relevant data regarding relapse rates, re-treatment rates, re-
sponse rates to treatment, and reasons why patients do not
receive radiotherapy as indicated. This would allow investi-
gators to estimate the actual rate of symptomatic recurrence
in a cohort and the proportion of those patients who would be
considered appropriate for re-treatment, thus facilitating an
estimation of an optimal re-treatment rate. Beside serving as
a benchmark, it can also aid with resource planning on a
wider level. It seems that, although the re-treatment rate for
patients with lung cancer approaches 36%, the actual number
of fractions delivered is only 17% of that given initially, and
the impact on workload may not be as considerable as first
thought. Data regarding the use of more modern staging
techniques and treatments would also give a more accurate
assessment of current relapse patterns and re-treatment prac-
tices. Finally, more accurate accounts of re-treatment rates for
investigators can aid them with future utilization studies,
giving them more confidence that they are accounting for
re-treatment accurately.
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